Bristol Myers bid for $1.2B Gilead patent award rejected by Supreme Court
lakshmiprasad S


Bristol Myers Squibb (NYSE:BMY) unit Juno Therapeutics Inc. failed to reinstate a $1.2B award it won from a patent dispute with Gilead (NASDAQ:GILD) subsidiary Kite Pharma Inc. over CAR-T therapy Yescarta as the U.S. Supreme Court rejected its bid on Monday.

In 2017, Juno and Sloan Kettering Institute for Cancer Research filed lawsuits in Los Angeles federal court, alleging that Kite copied the technology that the institute licensed to Juno.
The plaintiffs won $1.2B in damages which were subsequently declined by the U.S. Court of Appeals for the Federal Circuit in 2021.

The decision marks another development in legal issues surrounding biologics. Last week, the Supreme Court decided to hear a case over the patent rights for the cholesterol medication Repatha (evolocumab).